Insider transactions

EDGAR

Oruka Therapeutics, Inc.

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.

A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.

Window: transactions dated on or after 2025-11-20.

Open-market purchases (code P)
0 transactions, — shares
Open-market sales (code S)
145 transactions, 4,110,142 shares
Sum of shares × price per share: 343,710,303.0849

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

Showing 1–50 of 274

Insider transactions, newest first, as filed on SEC Forms 3, 4 and 5
DateReporting ownerCodeAcquired or disposedSharesPrice per share, as filedValue (derived)Shares owned afterDirect or indirectRule 10b5-1 boxNotesSource
2026-11-16 Filed 2026-11-16Goncalves Joana Officer: Chief Medical Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)3,5006.84
23,940

Derived: shares × price per share. Exact value 23940.00.

35,271Direct (D) Yes— Open filing 0000907654-26-000118 Read from the filing’s XML Dispute this row
2026-11-16 Filed 2026-11-16Goncalves Joana Officer: Chief Medical Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)3,5007.80
27,300

Derived: shares × price per share. Exact value 27300.00.

38,771Direct (D) Yes— Open filing 0000907654-26-000118 Read from the filing’s XML Dispute this row
2026-11-16 Filed 2026-11-16Goncalves Joana Officer: Chief Medical Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)2,60099.515
258,739

Derived: shares × price per share. Exact value 258739.000.

36,171Direct (D) Yes
F1, F2
  • F1 These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025.
  • F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.03 to $99.98, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6) and (7) to this Form 4.
Open filing 0000907654-26-000118 Read from the filing’s XML Dispute this row
2026-11-16 Filed 2026-11-16Goncalves Joana Officer: Chief Medical Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)1,500100.4792
150,718.8

Derived: shares × price per share. Exact value 150718.8000.

34,671Direct (D) Yes
F1, F3
  • F1 These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025.
  • F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $100.11 to $101.04, inclusive.
Open filing 0000907654-26-000118 Read from the filing’s XML Dispute this row
2026-11-16 Filed 2026-11-16Goncalves Joana Officer: Chief Medical Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)1,900101.5268
192,900.92

Derived: shares × price per share. Exact value 192900.9200.

32,771Direct (D) Yes
F1, F4
  • F1 These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025.
  • F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $101.11 to $102.09, inclusive.
Open filing 0000907654-26-000118 Read from the filing’s XML Dispute this row
2026-11-16 Filed 2026-11-16Goncalves Joana Officer: Chief Medical Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)300102.47
30,741

Derived: shares × price per share. Exact value 30741.00.

32,471Direct (D) Yes
F1, F5
  • F1 These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025.
  • F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $102.18 to $102.95, inclusive.
Open filing 0000907654-26-000118 Read from the filing’s XML Dispute this row
2026-11-16 Filed 2026-11-16Goncalves Joana Officer: Chief Medical Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)200103.36
20,672

Derived: shares × price per share. Exact value 20672.00.

32,271Direct (D) Yes
F1, F6
  • F1 These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025.
  • F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $103.26 to $103.46, inclusive.
Open filing 0000907654-26-000118 Read from the filing’s XML Dispute this row
2026-11-16 Filed 2026-11-16Goncalves Joana Officer: Chief Medical Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)500105.856
52,928

Derived: shares × price per share. Exact value 52928.000.

31,771Direct (D) Yes
F1, F7
  • F1 These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025.
  • F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.48 to $106.20, inclusive.
Open filing 0000907654-26-000118 Read from the filing’s XML Dispute this row
2026-11-16 Filed 2026-11-16Goncalves Joana Officer: Chief Medical Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (3,500) — exercise price 6.84
Disposed (D)3,5000—186,563Direct (D) Yes
F8
  • F8 The option vests as to 1/4 of the underlying shares on April 18, 2025 and as to 1/48 of the underlying shares monthly from April 18, 2025.
Open filing 0000907654-26-000118 Read from the filing’s XML Dispute this row
2026-11-16 Filed 2026-11-16Goncalves Joana Officer: Chief Medical Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Employee Warrant (right to buy) — underlying Common Stock (3,500) — exercise price 7.80
Disposed (D)3,5000—157,992Direct (D) Yes
F9
  • F9 The warrant vests as to 1/4 of the underlying shares on April 18, 2025 and as to 1/48 of the underlying shares monthly from April 18, 2025.
Open filing 0000907654-26-000118 Read from the filing’s XML Dispute this row
2026-11-12 Filed 2026-11-13Agarwal Arjun Officer: Senior Vice President, Finance
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)8,54212.5
106,775

Derived: shares × price per share. Exact value 106775.0.

22,761Direct (D) Yes— Open filing 0000907654-26-000116 Read from the filing’s XML Dispute this row
2026-11-12 Filed 2026-11-13Agarwal Arjun Officer: Senior Vice President, Finance
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)1,45834.39
50,140.62

Derived: shares × price per share. Exact value 50140.62.

24,219Direct (D) Yes— Open filing 0000907654-26-000116 Read from the filing’s XML Dispute this row
2026-11-12 Filed 2026-11-13Agarwal Arjun Officer: Senior Vice President, Finance
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)500101.9758
50,987.9

Derived: shares × price per share. Exact value 50987.9000.

23,719Direct (D) Yes
F1, F2
  • F1 These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026.
  • F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $101.28 to $102.22, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), and (6) to this Form 4.
Open filing 0000907654-26-000116 Read from the filing’s XML Dispute this row
2026-11-12 Filed 2026-11-13Agarwal Arjun Officer: Senior Vice President, Finance
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)801103.1556
82,627.6356

Derived: shares × price per share. Exact value 82627.6356.

22,918Direct (D) Yes
F1, F3
  • F1 These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026.
  • F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $102.75 to $103.70, inclusive.
Open filing 0000907654-26-000116 Read from the filing’s XML Dispute this row
2026-11-12 Filed 2026-11-13Agarwal Arjun Officer: Senior Vice President, Finance
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)799104.2502
83,295.9098

Derived: shares × price per share. Exact value 83295.9098.

22,119Direct (D) Yes
F1, F4
  • F1 These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026.
  • F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $103.75 to $104.65, inclusive.
Open filing 0000907654-26-000116 Read from the filing’s XML Dispute this row
2026-11-12 Filed 2026-11-13Agarwal Arjun Officer: Senior Vice President, Finance
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)6,842105.2806
720,329.8652

Derived: shares × price per share. Exact value 720329.8652.

15,277Direct (D) Yes
F1, F5
  • F1 These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026.
  • F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $104.82 to $105.81, inclusive.
Open filing 0000907654-26-000116 Read from the filing’s XML Dispute this row
2026-11-12 Filed 2026-11-13Agarwal Arjun Officer: Senior Vice President, Finance
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)958106.1759
101,716.5122

Derived: shares × price per share. Exact value 101716.5122.

14,319Direct (D) Yes
F1, F6
  • F1 These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026.
  • F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.82 to $106.52, inclusive.
Open filing 0000907654-26-000116 Read from the filing’s XML Dispute this row
2026-11-12 Filed 2026-11-13Agarwal Arjun Officer: Senior Vice President, Finance
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)100107.00
10,700

Derived: shares × price per share. Exact value 10700.00.

14,219Direct (D) Yes
F1
  • F1 These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026.
Open filing 0000907654-26-000116 Read from the filing’s XML Dispute this row
2026-11-12 Filed 2026-11-13Agarwal Arjun Officer: Senior Vice President, Finance
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (8,542) — exercise price 12.5
Disposed (D)8,5420—67,834Direct (D) Yes
F7
  • F7 The option vests as to 1/48 of the underlying shares monthly from January 1, 2025.
Open filing 0000907654-26-000116 Read from the filing’s XML Dispute this row
2026-11-12 Filed 2026-11-13Agarwal Arjun Officer: Senior Vice President, Finance
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (1,458) — exercise price 34.39
Disposed (D)1,4580—55,417Direct (D) Yes
F8
  • F8 The option vests as to 1/48 of the underlying shares monthly from January 1, 2026.
Open filing 0000907654-26-000116 Read from the filing’s XML Dispute this row
2026-11-12 Filed 2026-11-13BALL KRISTINE M Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)18,0006.84
123,120

Derived: shares × price per share. Exact value 123120.00.

18,000Direct (D) Yes— Open filing 0000907654-26-000115 Read from the filing’s XML Dispute this row
2026-11-12 Filed 2026-11-13BALL KRISTINE M Director
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)1,196102.0967
122,107.6532

Derived: shares × price per share. Exact value 122107.6532.

16,804Direct (D) Yes
F1, F2
  • F1 These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on August 12, 2026.
  • F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $101.62 to $102.61, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6) and (7) to this Form 4.
Open filing 0000907654-26-000115 Read from the filing’s XML Dispute this row
2026-11-12 Filed 2026-11-13BALL KRISTINE M Director
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)1,300103.0932
134,021.16

Derived: shares × price per share. Exact value 134021.1600.

15,504Direct (D) Yes
F1, F3
  • F1 These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on August 12, 2026.
  • F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $102.66 to $103.65, inclusive.
Open filing 0000907654-26-000115 Read from the filing’s XML Dispute this row
2026-11-12 Filed 2026-11-13BALL KRISTINE M Director
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)2,039104.1622
212,386.7258

Derived: shares × price per share. Exact value 212386.7258.

13,465Direct (D) Yes
F1, F4
  • F1 These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on August 12, 2026.
  • F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $103.69 to $104.65, inclusive.
Open filing 0000907654-26-000115 Read from the filing’s XML Dispute this row
2026-11-12 Filed 2026-11-13BALL KRISTINE M Director
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)10,765105.3141
1,133,706.2865

Derived: shares × price per share. Exact value 1133706.2865.

2,700Direct (D) Yes
F1, F5
  • F1 These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on August 12, 2026.
  • F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $104.76 to $105.75, inclusive.
Open filing 0000907654-26-000115 Read from the filing’s XML Dispute this row
2026-11-12 Filed 2026-11-13BALL KRISTINE M Director
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)2,500106.0520
265,130

Derived: shares × price per share. Exact value 265130.0000.

200Direct (D) Yes
F1, F6
  • F1 These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on August 12, 2026.
  • F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.76 to $106.46, inclusive.
Open filing 0000907654-26-000115 Read from the filing’s XML Dispute this row
2026-11-12 Filed 2026-11-13BALL KRISTINE M Director
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)200106.9850
21,397

Derived: shares × price per share. Exact value 21397.0000.

0Direct (D) Yes
F1, F7
  • F1 These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on August 12, 2026.
  • F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.97 to $107.00, inclusive.
Open filing 0000907654-26-000115 Read from the filing’s XML Dispute this row
2026-11-12 Filed 2026-11-13BALL KRISTINE M Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (18,000) — exercise price 6.84
Disposed (D)18,0000—53,426Direct (D) Yes
F8
  • F8 The option vests as to 1/4 of the underlying shares on May 7, 2025 and as to 1/48 of the underlying shares monthly from May 7, 2025.
Open filing 0000907654-26-000115 Read from the filing’s XML Dispute this row
2026-11-02 Filed 2026-11-02Klein Lawrence Otto Director · Officer: Chief Executive Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)25,0007.8
195,000

Derived: shares × price per share. Exact value 195000.0.

948,128Direct (D) Yes— Open filing 0000907654-26-000112 Read from the filing’s XML Dispute this row
2026-11-02 Filed 2026-11-02Klein Lawrence Otto Director · Officer: Chief Executive Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)6,46694.7718
612,794.4588

Derived: shares × price per share. Exact value 612794.4588.

941,662Direct (D) Yes
F1, F2
  • F1 These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 14, 2026.
  • F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.25 to $95.24, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5) and (6) to this Form 4.
Open filing 0000907654-26-000112 Read from the filing’s XML Dispute this row
2026-11-02 Filed 2026-11-02Klein Lawrence Otto Director · Officer: Chief Executive Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)15,03695.6363
1,437,987.4068

Derived: shares × price per share. Exact value 1437987.4068.

926,626Direct (D) Yes
F1, F3
  • F1 These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 14, 2026.
  • F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $95.25 to $96.23, inclusive.
Open filing 0000907654-26-000112 Read from the filing’s XML Dispute this row
2026-11-02 Filed 2026-11-02Klein Lawrence Otto Director · Officer: Chief Executive Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)2,44296.7021
236,146.5282

Derived: shares × price per share. Exact value 236146.5282.

924,184Direct (D) Yes
F1, F4
  • F1 These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 14, 2026.
  • F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $96.25 to $97.24, inclusive.
Open filing 0000907654-26-000112 Read from the filing’s XML Dispute this row
2026-11-02 Filed 2026-11-02Klein Lawrence Otto Director · Officer: Chief Executive Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)75697.4544
73,675.5264

Derived: shares × price per share. Exact value 73675.5264.

923,428Direct (D) Yes
F1, F5
  • F1 These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 14, 2026.
  • F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $97.30 to $98.12, inclusive.
Open filing 0000907654-26-000112 Read from the filing’s XML Dispute this row
2026-11-02 Filed 2026-11-02Klein Lawrence Otto Director · Officer: Chief Executive Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)30098.4033
29,520.99

Derived: shares × price per share. Exact value 29520.9900.

923,128Direct (D) Yes
F1, F6
  • F1 These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 14, 2026.
  • F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.40 to $98.41, inclusive.
Open filing 0000907654-26-000112 Read from the filing’s XML Dispute this row
2026-11-02 Filed 2026-11-02Klein Lawrence Otto Director · Officer: Chief Executive Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Employee Warrant (right to buy) — underlying Common Stock (25,000) — exercise price 7.8
Disposed (D)25,0000—1,503,513Direct (D) Yes
F7
  • F7 The warrant vests as to 1/4 of the underlying shares on April 3, 2025 and as to 1/48 of the underlying shares monthly from April 3, 2025.
Open filing 0000907654-26-000112 Read from the filing’s XML Dispute this row
2026-10-20 Filed 2026-10-20Quinlan Paul T Officer: General Counsel
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)9,0007.8
70,200

Derived: shares × price per share. Exact value 70200.0.

38,995Direct (D) Yes— Open filing 0000907654-26-000110 Read from the filing’s XML Dispute this row
2026-10-20 Filed 2026-10-20Quinlan Paul T Officer: General Counsel
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)40074.9007
29,960.28

Derived: shares × price per share. Exact value 29960.2800.

38,595Direct (D) Yes
F1, F2
  • F1 These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 15, 2026.
  • F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.47 to $75.30, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5) and (6) to this Form 4.
Open filing 0000907654-26-000110 Read from the filing’s XML Dispute this row
2026-10-20 Filed 2026-10-20Quinlan Paul T Officer: General Counsel
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)50076.118
38,059

Derived: shares × price per share. Exact value 38059.000.

38,095Direct (D) Yes
F1, F3
  • F1 These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 15, 2026.
  • F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.61 to $76.42, inclusive.
Open filing 0000907654-26-000110 Read from the filing’s XML Dispute this row
2026-10-20 Filed 2026-10-20Quinlan Paul T Officer: General Counsel
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)1,00077.205
77,205

Derived: shares × price per share. Exact value 77205.000.

37,095Direct (D) Yes
F1, F4
  • F1 These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 15, 2026.
  • F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.70 to $77.57, inclusive.
Open filing 0000907654-26-000110 Read from the filing’s XML Dispute this row
2026-10-20 Filed 2026-10-20Quinlan Paul T Officer: General Counsel
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)4,10078.7895
323,036.95

Derived: shares × price per share. Exact value 323036.9500.

32,995Direct (D) Yes
F1, F5
  • F1 These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 15, 2026.
  • F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.16 to $79.15, inclusive.
Open filing 0000907654-26-000110 Read from the filing’s XML Dispute this row
2026-10-20 Filed 2026-10-20Quinlan Paul T Officer: General Counsel
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)3,00079.4912
238,473.6

Derived: shares × price per share. Exact value 238473.6000.

29,995Direct (D) Yes
F1, F6
  • F1 These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 15, 2026.
  • F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.21 to $79.72, inclusive.
Open filing 0000907654-26-000110 Read from the filing’s XML Dispute this row
2026-10-20 Filed 2026-10-20Quinlan Paul T Officer: General Counsel
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Employee Warrant (right to buy) — underlying Common Stock (9,000) — exercise price 7.8
Disposed (D)9,0000—70,996Direct (D) Yes
F7
  • F7 The warrant vests as to 1/4 of the underlying shares on April 30, 2025 and as to 1/48 of the underlying shares monthly from April 30, 2025.
Open filing 0000907654-26-000110 Read from the filing’s XML Dispute this row
2026-10-15 Filed 2026-10-15Goncalves Joana Officer: Chief Medical Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)3,5006.84
23,940

Derived: shares × price per share. Exact value 23940.00.

35,271Direct (D) Yes— Open filing 0000907654-26-000108 Read from the filing’s XML Dispute this row
2026-10-15 Filed 2026-10-15Goncalves Joana Officer: Chief Medical Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)3,5007.80
27,300

Derived: shares × price per share. Exact value 27300.00.

38,771Direct (D) Yes— Open filing 0000907654-26-000108 Read from the filing’s XML Dispute this row
2026-10-15 Filed 2026-10-15Goncalves Joana Officer: Chief Medical Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)2,85373.8894
210,806.4582

Derived: shares × price per share. Exact value 210806.4582.

35,918Direct (D) Yes
F1, F2
  • F1 These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025.
  • F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.21 to $74.20, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5) and (6) to this Form 4.
Open filing 0000907654-26-000108 Read from the filing’s XML Dispute this row
2026-10-15 Filed 2026-10-15Goncalves Joana Officer: Chief Medical Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)1,84774.6924
137,956.8628

Derived: shares × price per share. Exact value 137956.8628.

34,071Direct (D) Yes
F1, F3
  • F1 These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025.
  • F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.22 to $75.18, inclusive.
Open filing 0000907654-26-000108 Read from the filing’s XML Dispute this row
2026-10-15 Filed 2026-10-15Goncalves Joana Officer: Chief Medical Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)1,40075.4834
105,676.76

Derived: shares × price per share. Exact value 105676.7600.

32,671Direct (D) Yes
F1, F4
  • F1 These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025.
  • F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.22 to $75.86, inclusive.
Open filing 0000907654-26-000108 Read from the filing’s XML Dispute this row
2026-10-15 Filed 2026-10-15Goncalves Joana Officer: Chief Medical Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)70076.6652
53,665.64

Derived: shares × price per share. Exact value 53665.6400.

31,971Direct (D) Yes
F1, F5
  • F1 These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025.
  • F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.27 to $77.23, inclusive.
Open filing 0000907654-26-000108 Read from the filing’s XML Dispute this row
2026-10-15 Filed 2026-10-15Goncalves Joana Officer: Chief Medical Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)20077.71
15,542

Derived: shares × price per share. Exact value 15542.00.

31,771Direct (D) Yes
F1, F6
  • F1 These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025.
  • F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.68 to $77.74, inclusive.
Open filing 0000907654-26-000108 Read from the filing’s XML Dispute this row
2026-10-15 Filed 2026-10-15Goncalves Joana Officer: Chief Medical Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Employee Stock Option (right to buy) — underlying Common Stock (3,500) — exercise price 6.84
Disposed (D)3,5000—190,063Direct (D) Yes
F7
  • F7 The option vests as to 1/4 of the underlying shares on April 18, 2025 and as to 1/48 of the underlying shares monthly from April 18, 2025.
Open filing 0000907654-26-000108 Read from the filing’s XML Dispute this row

Institutional holders (Form 13F)

Quarter ending 2026-09-30: 8,925 filings read, the latest filed 2026-11-19. Prior quarter ending 2026-06-30: 9,176 filings read.

Showing 1–50 of 273

Institutional holders, largest position first, as filed
ManagerShares or principalValue as filedChange from the prior quarterSource
FMR LLC Partly reported under another manager10,148,867 SH845,299,132 dollarsHigher by 1,091,222 Prior quarter: 9,057,645Open filing 0000315066-26-002964 Filed 2026-11-10 Dispute this row
BlackRock, Inc. Partly reported under another manager5,210,214 SH433,958,724 dollarsHigher by 220,033 Prior quarter: 4,990,181Open filing 0002012383-26-003985 Filed 2026-11-13 Dispute this row
T. Rowe Price Investment Management, Inc. 4,392,166 SH365,824 dollarsHigher by 3,288,423 Prior quarter: 1,103,743Open filing 0001897612-26-000766 Filed 2026-11-16 Dispute this row
Venrock Adviser, LLC 4,148,428 SH345,522,568 dollarsUnchanged Prior quarter: 4,148,428Open filing 0001615982-26-000019 Filed 2026-11-16 Dispute this row
Fairmount Funds Management LLC 3,705,262 SH308,611,272 dollarsUnchanged Prior quarter: 3,705,262Open filing 0001104659-26-128188 Filed 2026-11-16 Dispute this row
Capital World Investors Partly reported under another manager3,429,066 SH285,606,907 dollarsHigher by 27,427 Prior quarter: 3,401,639Open filing 0001422849-26-000169 Filed 2026-11-12 Dispute this row
RTW INVESTMENTS, LP 3,139,030 SH261,449,809 dollarsUnchanged Prior quarter: 3,139,030Open filing 0001493215-26-000214 Filed 2026-11-16 Dispute this row
STATE STREET CORP Partly reported under another manager2,817,132 SH234,617,269 dollarsHigher by 144,042 Prior quarter: 2,673,090Open filing 0000093751-26-000747 Filed 2026-11-12 Dispute this row
VANGUARD CAPITAL MANAGEMENT LLC 2,644,280 SH220,242,081 dollarsHigher by 283,309 Prior quarter: 2,360,971Open filing 0002100119-26-001711 Filed 2026-11-13 Dispute this row
Paradigm Biocapital Advisors LP 2,493,507 SH207,684,198 dollarsHigher by 348,981 Prior quarter: 2,144,526Open filing 0001855655-26-000020 Filed 2026-11-16 Dispute this row
FRANKLIN TEMPLETON INC Partly reported under another manager2,033,669 SH206,234,373 dollarsHigher by 412,218 Prior quarter: 1,621,451Open filing 0000038777-26-000291 Filed 2026-11-12 Dispute this row
Janus Henderson Group Ltd. Partly reported under another manager1,873,153 SH155,957,838 dollarsNot in the prior quarter’s filings read Open filing 0001085146-26-000952 Filed 2026-11-16 Dispute this row
Bellevue Group AG Partly reported under another manager1,641,059 SH136,683,804 dollarsLower by 16,131 Prior quarter: 1,657,190Open filing 0001104659-26-128575 Filed 2026-11-16 Dispute this row
VANGUARD PORTFOLIO MANAGEMENT LLC 1,592,427 SH132,633,245 dollarsHigher by 1,010,018 Prior quarter: 582,409Open filing 0002100121-26-001150 Filed 2026-11-13 Dispute this row
RA CAPITAL MANAGEMENT, L.P. 1,554,597 SH129,482,384 dollarsUnchanged Prior quarter: 1,554,597Open filing 0001104659-26-128411 Filed 2026-11-16 Dispute this row
GEODE CAPITAL MANAGEMENT, LLC Partly reported under another manager1,545,458 SH128,746,470 dollarsHigher by 115,504 Prior quarter: 1,429,954Open filing 0001214717-26-000012 Filed 2026-11-06 Dispute this row
Polar Capital Holdings Plc Partly reported under another manager1,224,841 SH102,017,007 dollarsLower by 3,768 Prior quarter: 1,228,609Open filing 0001172661-26-005169 Filed 2026-11-16 Dispute this row
PERCEPTIVE ADVISORS LLC 1,072,363 SH89,317,114 dollarsLower by 272,700 Prior quarter: 1,345,063Open filing 0001012975-26-001063 Filed 2026-11-16 Dispute this row
Deep Track Capital, LP 1,069,774 SH89,101,476 dollarsLower by 856,226 Prior quarter: 1,926,000Open filing 0001856083-26-000006 Filed 2026-11-16 Dispute this row
PRICE T ROWE ASSOCIATES INC /MD/ Partly reported under another manager966,767 SH80,523 dollarsHigher by 128,164 Prior quarter: 838,603Open filing 0000080255-26-000736 Filed 2026-11-16 Dispute this row
Remedium Capital Partners, LLC Partly reported under another manager954,150 SH79,471,154 dollarsLower by 611,511 Prior quarter: 1,565,661Open filing 0002104501-26-000021 Filed 2026-11-13 Dispute this row
WESTFIELD CAPITAL MANAGEMENT CO LP 829,749 SH69,109,794 dollarsHigher by 198,316 Prior quarter: 631,433Open filing 0001177719-26-000022 Filed 2026-11-12 Dispute this row
Avidity Partners Management LP 785,424 SH65,417,965 dollarsHigher by 25,000 Prior quarter: 760,424Open filing 0001791827-26-000008 Filed 2026-11-16 Dispute this row
SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC 723,922 SH60,295,463 dollarsHigher by 65,621 Prior quarter: 658,301Open filing 0001172661-26-005064 Filed 2026-11-16 Dispute this row
JPMORGAN CHASE CO Partly reported under another manager695,630 SH57,409,788 dollarsHigher by 40,603 Prior quarter: 655,027Open filing 0000019617-26-000404 Filed 2026-11-12 Dispute this row
Aberdeen Group plc Partly reported under another manager632,408 SH52,673,262 dollarsLower by 14,535 Prior quarter: 646,943Open filing 0001716774-26-000032 Filed 2026-11-10 Dispute this row
Affinity Asset Advisors, LLC 600,000 SH49,974,000 dollarsHigher by 10,000 Prior quarter: 590,000Open filing 0001011438-26-000687 Filed 2026-11-13 Dispute this row
GOLDMAN SACHS GROUP INC Partly reported under another manager582,289 SH48,498,851 dollarsHigher by 402,850 Prior quarter: 179,439Open filing 0000886982-26-000647 Filed 2026-11-16 Dispute this row
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 520,681 SH43,367,520 dollarsHigher by 87,276 Prior quarter: 433,405Open filing 0000884546-26-000417 Filed 2026-11-16 Dispute this row
BNP PARIBAS FINANCIAL MARKETS Partly reported under another manager459,528 SH38,274,087 dollarsLower by 619,487 Prior quarter: 1,079,015Open filing 0001166588-26-000012 Filed 2026-11-12 Dispute this row
NORTHERN TRUST CORP Partly reported under another manager446,386 SH37,179,490 dollarsHigher by 17,495 Prior quarter: 428,891Open filing 0000073124-26-000067 Filed 2026-11-16 Dispute this row
VOYA INVESTMENT MANAGEMENT LLC Partly reported under another manager412,814 SH34,383,278 dollarsHigher by 11,665 Prior quarter: 401,149Open filing 0001068837-26-000006 Filed 2026-11-10 Dispute this row
VANGUARD FIDUCIARY TRUST CO 403,555 SH33,612,096 dollarsHigher by 37,925 Prior quarter: 365,630Open filing 0000933478-26-000017 Filed 2026-11-13 Dispute this row
Pictet Asset Management Holding SA 401,928 SH33,475,789 dollarsLower by 217,148 Prior quarter: 619,076Open filing 0001993888-26-000007 Filed 2026-11-03 Dispute this row
Cormorant Asset Management, LP Partly reported under another manager400,000 SH33,316,000 dollarsLower by 133,340 Prior quarter: 533,340Open filing 0001583977-26-000011 Filed 2026-11-16 Dispute this row
ADAGE CAPITAL PARTNERS GP, L.L.C. 394,246 SH32,836,749 dollarsHigher by 39,243 Prior quarter: 355,003Open filing 0001172661-26-005200 Filed 2026-11-16 Dispute this row
Point72 Asset Management, L.P. 373,455 SH31,105,067 dollarsNot in the prior quarter’s filings read Open filing 0000919574-26-008126 Filed 2026-11-16 Dispute this row
MASSACHUSETTS FINANCIAL SERVICES CO /MA/ Partly reported under another manager345,003 SH28,735,300 dollarsLower by 19,099 Prior quarter: 364,102Open filing 0000912938-26-001073 Filed 2026-11-12 Dispute this row
Candriam S.C.A. 339,032 SH28,341,147 dollarsLower by 13,684 Prior quarter: 352,716Open filing 0001537014-26-000009 Filed 2026-11-03 Dispute this row
UBS Group AG Partly reported under another manager320,044 SH26,656,465 dollarsLower by 319,319 Prior quarter: 639,363Open filing 0001610520-26-000121 Filed 2026-11-10 Dispute this row
BRAIDWELL LP 319,679 SH26,626,064 dollarsHigher by 41,515 Prior quarter: 278,164Open filing 0001420506-26-002894 Filed 2026-11-16 Dispute this row
LORD, ABBETT CO. LLC 306,236 SH25,506 dollarsLower by 83,828 Prior quarter: 390,064Open filing 0000930413-26-003314 Filed 2026-11-13 Dispute this row
JENNISON ASSOCIATES LLC Partly reported under another manager301,727 SH25,130,843 dollarsHigher by 2,470 Prior quarter: 299,257Open filing 0000053417-26-000068 Filed 2026-11-16 Dispute this row
Ghisallo Capital Management LLC 300,000 SH24,987,000 dollarsHigher by 250,000 Prior quarter: 50,000Open filing 0001172661-26-005475 Filed 2026-11-19 Dispute this row
MPM BIOIMPACT LLC 300,000 SH24,987,000 dollarsNot in the prior quarter’s filings read Open filing 0001193125-26-463462 Filed 2026-11-16 Dispute this row
Caption Management, LLC Option: Put 300,000 SH24,987,000 dollarsNot in the prior quarter’s filings read Open filing 0001706766-26-000008 Filed 2026-11-16 Dispute this row
EVENTIDE ASSET MANAGEMENT, LLC 295,000 SH24,570,550 dollarsHigher by 55,000 Prior quarter: 240,000Open filing 0001580642-26-007711 Filed 2026-11-13 Dispute this row
Holocene Advisors, LP 291,573 SH24,285,115 dollarsLower by 14,378 Prior quarter: 305,951Open filing 0001172661-26-005338 Filed 2026-11-16 Dispute this row
Woodline Partners LP 285,952 SH23,816,942 dollarsHigher by 705 Prior quarter: 285,247Open filing 0001172661-26-005063 Filed 2026-11-16 Dispute this row
BANK OF AMERICA CORP /DE/ Partly reported under another manager281,363 SH23,434,724 dollarsLower by 71,461 Prior quarter: 352,824Open filing 0000070858-26-000589 Filed 2026-11-16 Dispute this row
Managers in the prior quarter with no filing read for the latest

They may simply not have filed yet: absent from the latest quarter’s filings read is not the same as a position sold.

  • Jupiter Topco LLC 1,375,844 SH
  • Sixth Street Partners Management Company, L.P. 433,405 SH
  • Siren, L.L.C. 250,000 SH
  • Sio Capital Management, LLC 177,118 SH
  • PFM Health Sciences, LP 158,825 SH
  • First Turn Management, LLC 155,343 SH
  • ExodusPoint Capital Management, LP 148,212 SH
  • Atika Capital Management LLC 100,000 SH
  • Alyeska Investment Group, L.P. 87,744 SH
  • Trexquant Investment LP 49,616 SH
  • Schonfeld Strategic Advisors LLC 34,860 SH
  • Freestone Grove Partners LP 22,421 SH
  • GLENMEDE TRUST CO NA 22,096 SH
  • ADAR1 Capital Management, LLC 20,840 SH
  • SG Americas Securities, LLC 14,576 SH
  • AXXCESS WEALTH MANAGEMENT, LLC 14,515 SH
  • Sound Capital Solutions LLC 13,396 SH
  • OPTIMIZE FINANCIAL INC. 13,396 SH
  • Brookwood Investment Group LLC 12,990 SH
  • Rock Springs Capital Management LP 12,051 SH
  • Stonepine Capital Management, LLC 7,500 SH
  • Arrowpoint Investment Partners (Singapore) Pte. Ltd. 6,315 SH
  • AMERICAN CENTURY COMPANIES INC 4,948 SH
  • Ground Swell Capital, LLC 4,320 SH
  • Quadrature Capital Ltd 4,290 SH
  • Engineers Gate Manager LP 3,680 SH
  • Belvedere Trading LLC 3,531 SH
  • Gradient Investments LLC 2,868 SH
  • COMMONWEALTH EQUITY SERVICES, LLC 2,332 SH
  • FOX RUN MANAGEMENT, L.L.C. 2,247 SH
  • State of Wyoming 2,242 SH
  • NATURAL INVESTMENTS, LLC 2,125 SH
  • MERCER GLOBAL ADVISORS INC /ADV 1,077 SH
  • Belvedere Trading LLC 800 SH
  • Belvedere Trading LLC 800 SH
  • Pacer Advisors, Inc. 720 SH
  • Optiver Holding B.V. 284 SH
  • GROUP ONE TRADING LLC 136 SH
  • Aster Capital Management (DIFC) Ltd 105 SH
  • GROUP ONE TRADING LLC 100 SH
  • Integrated Wealth Concepts LLC 71 SH
  • COMPASS FINANCIAL MANAGEMENT LLC 38 SH
  • Key Capital Management, INC 24 SH
  • Ares Financial Consulting, LLC 7 SH
  • NATIONAL BANK OF CANADA /FI/ 5 SH
  • Form 13F covers long positions in Section 13(f) securities only: no short positions and no securities outside that list.
  • Reports for quarters ending before 2013-06-30 were filed as plain text and are not read.
  • A manager that has not yet filed for the latest quarter is absent, not at zero; filings are due up to 45 days after quarter end.
  • A change is the difference between two quarter-end snapshots, not a trade.
  • A position reported under another manager may also appear in that manager’s filing; rows are not added together.
  • Holdings the securities list cannot place with this company, or places ambiguously, are not shown.

Trades by members of Congress

Periodic transaction reports filed by U.S. House members that name this company’s stock. Dates and amounts are as filed.

No House member’s trade in this company is placed in the store. A trade not yet filed or not linked to a company is absent, not zero.

5% holders (Schedule 13D and 13G)

Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.

5% holders, newest event first, as filed
HolderPercent of classShares heldEvent dateFormSource
RTW Investments, LP Common Stock, $0.001 par value4.73,139,030.0009/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 1Open filing 0001493215-26-000198 Dispute this row
Roderick Wong Common Stock, $0.001 par value4.73,139,030.0009/30/2026 Filed 2026-11-16SCHEDULE 13G/AAmendment 1Open filing 0001493215-26-000198 Dispute this row
T. Rowe Price Investment Management, Inc. COMMON STOCK6.64,392,16609/30/2026 Filed 2026-11-16SCHEDULE 13GOpen filing 0001897612-26-000718 Dispute this row
Fairmount Funds Management LLC Common Stock, $0.001 par value per share19.4714,553,895.0007/01/2026 Filed 2026-07-01SCHEDULE 13D/AAmendment 6Open filing 0001104659-26-080010 Dispute this row
Fairmount Healthcare Fund II L.P. Common Stock, $0.001 par value per share16.0311,980,587.0007/01/2026 Filed 2026-07-01SCHEDULE 13D/AAmendment 6Open filing 0001104659-26-080010 Dispute this row
Fairmount Healthcare Co-Invest III L.P. Common Stock, $0.001 par value per share4.032,573,308.0007/01/2026 Filed 2026-07-01SCHEDULE 13D/AAmendment 6Open filing 0001104659-26-080010 Dispute this row
Harwin Peter Evan Common Stock, $0.001 par value per share19.5014,572,917.0007/01/2026 Filed 2026-07-01SCHEDULE 13D/AAmendment 6Open filing 0001104659-26-080010 Dispute this row
Kiselak Tomas Common Stock, $0.001 par value per share19.4714,533,895.0007/01/2026 Filed 2026-07-01SCHEDULE 13D/AAmendment 6Open filing 0001104659-26-080010 Dispute this row
VIKING GLOBAL INVESTORS LP Common Stock, $0.001 par value per share2.51,503,47806/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 2Open filing 0000905148-26-003735 Dispute this row
Viking Global Opportunities Parent GP LLC Common Stock, $0.001 par value per share2.51,503,47806/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 2Open filing 0000905148-26-003735 Dispute this row
Viking Global Opportunities GP LLC Common Stock, $0.001 par value per share1.5902,08706/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 2Open filing 0000905148-26-003735 Dispute this row
Viking Global Opportunities Portfolio GP LLC Common Stock, $0.001 par value per share1.5902,08706/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 2Open filing 0000905148-26-003735 Dispute this row
Viking Global Opportunities Illiquid Investments Sub-Master LP Common Stock, $0.001 par value per share1.5902,08706/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 2Open filing 0000905148-26-003735 Dispute this row
Viking Global Opportunities Drawdown GP LLC Common Stock, $0.001 par value per share1601,39106/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 2Open filing 0000905148-26-003735 Dispute this row
Viking Global Opportunities Drawdown Portfolio GP LLC Common Stock, $0.001 par value per share1601,39106/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 2Open filing 0000905148-26-003735 Dispute this row
Viking Global Opportunities Drawdown (Aggregator) LP Common Stock, $0.001 par value per share1601,39106/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 2Open filing 0000905148-26-003735 Dispute this row
HALVORSEN OLE ANDREAS Common Stock, $0.001 par value per share2.51,503,47806/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 2Open filing 0000905148-26-003735 Dispute this row
Shabet Rose Sharon Common Stock, $0.001 par value per share2.51,503,47806/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 2Open filing 0000905148-26-003735 Dispute this row
RTW Investments, LP Common Stock, $0.001 par value5.23,139,030.0006/30/2026 Filed 2026-08-14SCHEDULE 13GOpen filing 0001493215-26-000153 Dispute this row
Roderick Wong Common Stock, $0.001 par value5.23,139,030.0006/30/2026 Filed 2026-08-14SCHEDULE 13GOpen filing 0001493215-26-000153 Dispute this row
Venrock Healthcare Capital Partners III, L.P. Common Stock, par value $0.001 per share7.44,556,952.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 4Open filing 0001231919-26-000934 Dispute this row
VHCP Co-Investment Holdings III, LLC Common Stock, par value $0.001 per share7.44,556,952.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 4Open filing 0001231919-26-000934 Dispute this row
Venrock Healthcare Capital Partners EG, L.P. Common Stock, par value $0.001 per share7.44,556,952.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 4Open filing 0001231919-26-000934 Dispute this row
VHCP Management III, LLC Common Stock, par value $0.001 per share7.44,556,952.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 4Open filing 0001231919-26-000934 Dispute this row
VHCP Management EG, LLC Common Stock, par value $0.001 per share7.44,556,952.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 4Open filing 0001231919-26-000934 Dispute this row
Nimish Shah Common Stock, par value $0.001 per share7.44,556,952.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 4Open filing 0001231919-26-000934 Dispute this row
Bong Y. Koh Common Stock, par value $0.001 per share7.44,556,952.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 4Open filing 0001231919-26-000934 Dispute this row
Capital World Investors Common Stock5.63,401,639.0006/30/2026 Filed 2026-08-12SCHEDULE 13GOpen filing 0001422849-26-000148 Dispute this row
Fairmount Funds Management LLC Common Stock, $0.001 par value per share19.9913,665,080.0004/30/2026 Filed 2026-05-04SCHEDULE 13D/AAmendment 5Open filing 0001104659-26-055049 Dispute this row
Fairmount Healthcare Fund II L.P. Common Stock, $0.001 par value per share16.2311,091,772.0004/30/2026 Filed 2026-05-04SCHEDULE 13D/AAmendment 5Open filing 0001104659-26-055049 Dispute this row
Fairmount Healthcare Co-Invest III L.P. Common Stock, $0.001 par value per share4.412,573,308.0004/30/2026 Filed 2026-05-04SCHEDULE 13D/AAmendment 5Open filing 0001104659-26-055049 Dispute this row
Harwin Peter Evan Common Stock, $0.001 par value per share19.9913,660,663.0004/30/2026 Filed 2026-05-04SCHEDULE 13D/AAmendment 5Open filing 0001104659-26-055049 Dispute this row
Kiselak Tomas Common Stock, $0.001 par value per share19.9913,665,080.0004/30/2026 Filed 2026-05-04SCHEDULE 13D/AAmendment 5Open filing 0001104659-26-055049 Dispute this row
VIKING GLOBAL INVESTORS LP Common Stock, $0.001 par value per share5.32,666,69003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 1Open filing 0000905148-26-002436 Dispute this row
Viking Global Opportunities Parent GP LLC Common Stock, $0.001 par value per share5.32,666,69003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 1Open filing 0000905148-26-002436 Dispute this row
Viking Global Opportunities GP LLC Common Stock, $0.001 par value per share3.21,600,01403/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 1Open filing 0000905148-26-002436 Dispute this row
Viking Global Opportunities Portfolio GP LLC Common Stock, $0.001 par value per share3.21,600,01403/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 1Open filing 0000905148-26-002436 Dispute this row
Viking Global Opportunities Illiquid Investments Sub-Master LP Common Stock, $0.001 par value per share3.21,600,01403/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 1Open filing 0000905148-26-002436 Dispute this row
Viking Global Opportunities Drawdown GP LLC Common Stock, $0.001 par value per share2.11,066,67603/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 1Open filing 0000905148-26-002436 Dispute this row
Viking Global Opportunities Drawdown Portfolio GP LLC Common Stock, $0.001 par value per share2.11,066,67603/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 1Open filing 0000905148-26-002436 Dispute this row
Viking Global Opportunities Drawdown (Aggregator) LP Common Stock, $0.001 par value per share2.11,066,67603/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 1Open filing 0000905148-26-002436 Dispute this row
HALVORSEN OLE ANDREAS Common Stock, $0.001 par value per share5.32,666,69003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 1Open filing 0000905148-26-002436 Dispute this row
Shabet Rose Sharon Common Stock, $0.001 par value per share5.32,666,69003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 1Open filing 0000905148-26-002436 Dispute this row
The Vanguard Group Common Stock0003/13/2026 Filed 2026-03-27SCHEDULE 13G/AAmendment 1Open filing 0000102909-26-001923 Dispute this row
RTW Investments, LP Common Stock, $0.001 par value4.32,058,148.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 1Open filing 0001493215-26-000040 Dispute this row
Roderick Wong Common Stock, $0.001 par value4.32,058,148.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 1Open filing 0001493215-26-000040 Dispute this row
Deep Track Capital, LP Common stock, $0.001 Par Value4.472,161,510.0012/31/2025 Filed 2026-02-13SCHEDULE 13G/AAmendment 1Open filing 0001172661-26-000719 Dispute this row
Deep Track Biotechnology Master Fund, Ltd. Common stock, $0.001 Par Value3.921,899,455.0012/31/2025 Filed 2026-02-13SCHEDULE 13G/AAmendment 1Open filing 0001172661-26-000719 Dispute this row
David Kroin Common stock, $0.001 Par Value4.472,161,510.0012/31/2025 Filed 2026-02-13SCHEDULE 13G/AAmendment 1Open filing 0001172661-26-000719 Dispute this row
Deep Track Special Opportunities Fund, LP. Common stock, $0.001 Par Value0.54262,055.0012/31/2025 Filed 2026-02-13SCHEDULE 13G/AAmendment 1Open filing 0001172661-26-000719 Dispute this row

Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.

What was read

2,660,713 filings read, dated 2004-06-14 to 2026-11-19: Forms 3, 3/A, 4, 4/A, 5, 5/A.

Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.

Filings read, by filing year
Filing yearFilings read
201577,800
2016222,642
2017222,009
2018223,345
2019216,482
2020226,343
2021249,835
2022231,682
2023229,674
2024234,045
2025235,520
2026263,123

Filings made before the SEC required XML are listed, not extracted.

Back to Oruka Therapeutics, Inc.